Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mitoguazone (Methyl-GAG) is a selective S-adenosyl-methionine decarboxylase inhibitor that penetrates the blood-brain barrier and disrupts polyamine biosynthesis. Mitoguazone is a synthetic polycarbonyl derivative with anti-tumor activity that inhibits the integration of HIV DNA into cellular DNA in monocytes and macrophages, inducing apoptosis. Mitoguazone can be used to prevent acute leukemia, Hodgkin lymphoma and non-Hodgkin lymphoma.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
2 mg | 在庫あり | ¥ 16,000 |
5 mg | 約 5 days | ¥ 27,500 |
10 mg | 約 5 days | ¥ 41,000 |
25 mg | 約 5 days | ¥ 74,500 |
50 mg | 約 5 days | ¥ 113,000 |
100 mg | 約6-8 週間 | ¥ 165,000 |
500 mg | 約 5 days | ¥ 337,500 |
説明 | Mitoguazone (Methyl-GAG) is a selective S-adenosyl-methionine decarboxylase inhibitor that penetrates the blood-brain barrier and disrupts polyamine biosynthesis. Mitoguazone is a synthetic polycarbonyl derivative with anti-tumor activity that inhibits the integration of HIV DNA into cellular DNA in monocytes and macrophages, inducing apoptosis. Mitoguazone can be used to prevent acute leukemia, Hodgkin lymphoma and non-Hodgkin lymphoma. |
In vitro |
At concentrations as low as 0.5 μg/mL, Mitoguazone competitively inhibits spermidine synthesis in lymphocytes. At levels of 30 μg/mL or higher, it inhibits protein synthesis and mitochondrial respiration[5]. The ability of Mitoguazone to induce apoptosis by inhibiting the polyamine pathway was evaluated in three Burkitt lymphoma cell lines (Raji, Ramos, and Daudi) and a prostate cancer cell line (MPC 3). Mitoguazone induces apoptosis in a concentration- and time-dependent manner in all tested human cancer cell lines, and triggers p53-independent programmed cell death in the human breast cancer MCF7 cell line[2]. |
In vivo | The impact of different stages of leukemia (P388) on the pharmacokinetics of the anti-tumor drug Mitoguazone was investigated in mice. Regardless of the tumor stage under study, there was a slight reduction in the total clearance rate of Mitoguazone, reflecting a moderate increase in the AUC in the serum of leukemia-afflicted animals. Additionally, at the late tumor stage, the drug levels in the kidneys, liver, spleen, and serum were somewhat higher compared to early-stage leukemia, and were elevated to a certain extent compared to the tumor-free control[1]. |
別名 | MGBG, Methyl-GAG |
分子量 | 184.2 |
分子式 | C5H12N8 |
CAS No. | 459-86-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 50 mg/mL (271.44 mM), when pH is adjusted to 9 with HCl. Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Mitoguazone 459-86-9 Apoptosis Microbiology/Virology Proteases/Proteasome HIV Protease MGBG Methyl-GAG Inhibitor inhibitor inhibit